Table 1.
Ongoing clinical trials of immunotherapy on liver cancer.
| NCT Number | Study Type | Phase | Status | Sample Size(n) | Conditions | Outcome Measures |
|---|---|---|---|---|---|---|
| NCT05109052 | Interventional | I/II | Withdrawn | 48 | HCC | Safety and Tolerability |
| NCT05185505 | Interventional | IV | Recruiting | 24 | HCC | 1 Acute Rejection 2 AE 3 ORR 4 atezolizumab/bevacizumab therapy 5 liver transplantation 6 necrotic tumors 7 RFS 8 OS 9 Tumor biomarkers 10 Immune Cell Biomarkers |
| NCT05609695 | Observational | NA | Not yet recruiting | 100 | HCC | 1 OS 2 TR 3 PFS |
| NCT05942560 | Interventional | NA | Not yet recruiting | 160 | Depression, Anxiety, HCC, CBT | 1 Depression symptoms 2 Anxiety symptoms 3 Quality of life score 4 Immune variables 5 OS |
| NCT05873244 | Interventional | II | Recruiting | 44 | HCC | 1 PFS 2 OS 3 radiological response rate 4 time-to-progression 5 AE |
| NCT05443230 | Observational | NA | Enrolling by invitation | 200 | HCC, Sarcopenia | 1 Short-term results 2 Long-term results |
| NCT05717400 | Interventional | IV | Recruiting | 15 | HCC | 1 Overall Response Rate |
| NCT05484908 | Interventional | NA | Not yet recruiting | 60 | HCC, Liver Failure, Immune-Mediated Hepatitis | 1 Mortality rate 2 Model for end-stage liver disease (MELD) score variation |
| NCT06045286 | Interventional | I | Recruiting | 30 | Colorectal Liver Metastases | 1 ORR 2 PFS 3 OS |
| NCT06199232 | Interventional | NA | Not yet recruiting | 47 | Liver Metastasis Colon Cancer, Failed From Standard Treatment, MSS, ctDNA Genotype | 1 PFS 2 OS 3 ORR 4 DCR 5 AE |
| NCT05550090 | Observational | NA | Recruiting | 40 | Metastatic Breast Cancer in the Liver | 1 Correlation between DCE-MRI parameters combined with IVIM parameters and efficacy of chemotherapy in patients with liver metastasis of breast cancer |
| NCT05438420 | Interventional | I/II | Recruiting | 120 | HCC, Cervical Cancer, Esophageal Cancer, Gastric Cancer | 1 AE 2 TR 3 Change in the area under curve (AUC) of Q702 and its primary metabolites |
| NCT06047015 | Interventional | I/II | Not yet recruiting | 12 | Liver Metastasis Colon Cancer | 1 Complications 2 Abscopal effect 3 Tumor-specific immune response 4 PFS 5 Quality of life questionnaire |
| NCT05677113 | Interventional | II | Recruiting | 115 | Liver Metastases, Colorectal Cancer | 1 PFS 2 Clearance of ctDNA 3 Side-effect profile of QBECO 4 Quality of recovery 5 Five-year overall survival |
| NCT05833126 | Interventional | II | Recruiting | 25 | Recurrent Liver Cancer After Liver Transplantation | 1 Acute graft rejection rate 2 ORR 3 OS 4 PFS 5 Time to Progression 6 SAE 7 Graft Rejection |
| NCT05451043 | Interventional | II | Not yet recruiting | 62 | HCC, Biliary Tract Cancer, Pancreatic Cancer, Cholangiocarcinoma | 1 Investigating and establishing the efficacy of propranolol in boosting the effects of immunotherapy 2 Feasibility of study therapy 3 Safety/tolerability 4 PFS 5 OS |
| NCT05039736 | Interventional | II | Withdrawn | 0 | HCC | 1 overall response rate |
| NCT05893056 | Interventional | II | Recruiting | 25 | Gastric Cancer Metastatic to Liver | 1 ORR 2 DOR 3 PFS 4 OS 5 DCR 6 Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 |
| NCT05169957 | Interventional | I | Recruiting | 18 | Liver Metastases, Melanoma, Cutaneous, Melanoma, Mucosal, Melanoma, Ocular, Metastatic Melanoma | 1 Percentage of patients who receive all planned radiotherapy 2 Proportion of patients who develop grade 3 or higher toxicity 3 OS 4 PFS 5 Proportion of patients with local control 6 ORR 7 BOR |
| NCT06117891 | Observational | NA | Recruiting | 300 | Unresectable Hepatocellular Carcinoma | 1 OS 2 Discriptive analysis 3 DOT 4 PFS 5 ORR 6 Treatment sequences post first-line AB or other IO combinations |
| NCT05588297 | Interventional | II | Not yet recruiting | 12 | Colorectal Cancer Liver Metastases | 1 R0 recession rate 2 Pathological complete response rate 3 TRG 4 ORR 5 EFS 6 DFS 7 OS 7 AE 8 Quality of life score |
| NCT05322187 | Interventional | II/III | Not yet recruiting | 15 | HCC, Hepatoblastoma, Pediatric Cancer, Pediatric Solid Tumor, Transitional Cell Tumor | 1 ORR 2 dynamic α-fetoprotein response (AFP-R) 3 AE 4 Health outcomes as assessed by the PROMIS® Pediatric Scale v1.0 Global Health 7 + 2 scores at baseline |
| NCT05510427 | Interventional | I | Withdrawn | 0 | HCC, Cholangiocarcinoma | 1 AE 2 MTD |
| NCT05984511 | Interventional | NA | Not yet recruiting | 234 | HCC, Tumor Thrombus, Hepatic Portal Vein Tumor Invasion | 1 OS 2 PFS 3 ORR 4 Duration of portal patency 5 AE |
| NCT05653531 | Interventional | NA | Withdrawn | 0 | Liver Biomarkers, ICI, Lung Cancer, Transaminases | 1 basal ALT blood concentration in lung cancer patients treated with ICI determined |
| NCT05233358 | Interventional | NA | Not yet recruiting | 176 | HCC | 1 PFS 2 OS 3 To Tumor Untreatable Progression 4 ORR 5 DCR 6 DOR 7 AE |
| NCT05339581 | Interventional | NA | Not yet recruiting | 78 | HCC, Liver Transplant; Complications, Portal Vein Thrombosis, Radiotherapy; Complications | 1 PVTT RR/NR 2 Alpha Fetoprotein Response (AFP-R) 3 PFS 4 ORR 5 TTP 6 DOR |
| NCT05411133 | Interventional | I | Recruiting | 68 | HCC, Cholangiocarcinoma, Colorectal Adenocarcinoma, Esophageal Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction, Gastrointestinal Cancer, Pancreatic Cancer | 1 AE 2 Amount of Cabotamig (ARB202) in plasma 3 Biochemical and physiological effects 4 Effect of Cabotamig (ARB202) on tumour |
| NCT05937295 | Interventional | I | Recruiting | 20 | Fibrolamellar Hepatocellular Carcinoma | 1 To assess immunogenicity in terms of induction of peptide specific T-cell responses 2 Safety and Tolerability |
| NCT05332496 | Observational [Patient Registry] | NA | Recruiting | 220 | HCC | 1 PFS 2 OS 3 ORR 4 DOR 5 DCR 6 AE |
| NCT05332821 | Observational [Patient Registry] | NA | Recruiting | 474 | HCC | 1 OS 2 PFS 3 ORR 4 DOR 5 DCR 6 AE |
| NCT05647954 | Interventional | III | Not yet recruiting | 350 | Melanoma Neuroendocrine Tumors Neuroectodermal Tumors, Neoplasms Germ Cell and Embryonal Neoplasms by Histologic Type, Neoplasms Neoplasms | 1 PFS 2 OS 3 ORR 4 DCR 5 DOR 6 PFS 7 OS 8 AE |
| NCT05810402 | Interventional | NA | Not yet recruiting | 60 | HCC, ICI, Liquid Biopsy | 1 Percentage of patients with CTCs-PD-L1+ by CellSearch® technique 2 OS 3 PFS |
| NCT06031480 | Interventional | II | Not yet recruiting | 55 | HCC | 1 ORR |
| NCT04430452 | Interventional | II | Recruiting | 21 | HCC | 1 ORR 2 AE 3 PFS 4 DOR 5 OS |
| NCT06040177 | Interventional | I/II | Recruiting | 30 | HCC Non-resectable, ICI, Portal Vein Tumor Thrombus | 1 ORR 2 PFS 3 DCR 4 DOR 5 OS |
| NCT06205706 | Interventional | I/II | Recruiting | 104 | HCC, Non Small Cell Lung Cancer, Solid Tumors | 1 AE 2 SAE 3 Frequency of dose interruptions and dose reductions 4 DLT |
| NCT05278195 | Observational | NA | Recruiting | 300 | HCC | 1 OS 2 Specificity 3 Sensitivity 4 The area under curve (AUC) of Receiver Operating Characteristic (ROC) curves of the radiomics artificial intelligence mode 5 Accuracy |
| NCT05406466 | Interventional | II | Recruiting | 25 | Melanoma | 1 ORR 2 DCR 3 DOR 4 TTR 5 PFS 6 OS 7 AE |
| NCT05070247 | Interventional | I/II | Recruiting | 313 | HCC, Breast Cancer, Esophageal Cancer, Gastric Cancer, Kidney Cancer, Mesothelioma, Nasopharyngeal Cancer, Non-small Cell Lung Cancer (NSCLC), Non-squamous, Pancreatic Cancer, Squamous Cell Cancer of Head and Neck (SCCHN) |
1 Dose Escalation 2 Dose Expansion: Overall Response Rate (ORR) 3 DCR 4 DOR 5 TTR 6 PFS 7 OS 8 AE |
| NCT05665348 | Interventional | II/III | Not yet recruiting | 574 | HCC, Metastatic Tumor | 1 Objective response of treatment 2 OS 3 PFS 4 OR |
| NCT05879328 | Observational | NA | Recruiting | 12 | HCC | 1 RFS 2 TR 3 Complication rate 4 OS 5 Patients’ reported outcomes (PROs) 6 Comparison with historical series |
| NCT04777851 | Interventional | III | Recruiting | 496 | HCC | 1 PFS 2 OS 3 ORR 4 Time to unTACEable Progression (TTUP) 5 DOR |
| NCT04965714 | Interventional | II | Withdrawn | 0 | Resectable HCC | 1 AE 2 Rate of pathologic complete response 3 Necrosis of tumors 4 TTP 5 RFS 6 OS |
| NCT06041477 | Interventional | III | Recruiting | 540 | HCC, Chemotherapeutic Toxicity, Chemotherapy Effect | 1 PFS 2 OS 3 ORR 4 DCR 5 CRR 6 Safety profiles of all participants |
| NCT05897268 | Interventional | II | Recruiting | 25 | HCC | 1 ORR 2 PFS 3 OS 4 DOR 5 DCR 6 ORR 7 PFS 8 OS 9 AE |
| NCT05096715 | Interventional | I | Not yet recruiting | 20 | Unresectable HCC | 1 Dose Limiting Toxicity Rate 2 PFS 3 OS 4 In-field response rate 5 Change in Child-Pugh Score 6 Out of field response rate |
| NCT05092373 | Interventional | I | Recruiting | 36 | too much | 1 To assess the safety and tolerability of TTF, including the maximum tolerated dose (MTD) 2 ORR 3 PFS 4 OS |
| NCT05578430 | Interventional | II | Not yet recruiting | 54 | Resectable HCC | 1 MPR 2 RFS 3 ORR 4 AE |
| NCT05044676 | Observational | NA | Recruiting | 120 | HCC | 1 OS |
| NCT05516628 | Interventional | II | Not yet recruiting | 30 | HCC | 1 RFS 2 TTR 3 RFS 4 OS |
| NCT06218511 | Interventional | I | Recruiting | 10 | HCC | 1 DFS 2 PFS 3 OS 4 AE |
| NCT05625893 | Interventional | II | Recruiting | 63 | HCC, Portal Vein Thrombosis | 1 PFS 2 AE 3 OS 4 Time-to-progression 5 ORR 6 DCR 7 Local tumor progression rate |
| NCT04965454 | Interventional | II | Recruiting | 80 | HCC Non-resectable | 1 ORR 2 DCR |
| NCT05337137 | Interventional | I/II | Recruiting | 162 | HCC | 1 DLT 2 ORR 3 PFS |
| NCT06133062 | Interventional | II | Recruiting | 45 | HCC Non-resectable | 1 PFS 2 LC 3 TTP 4 ORR 5 OS 6 AE |
| NCT05537402 | Interventional | II | Recruiting | 204 | HCC | 1 PFS 2 ORR 3 OS |
| NCT05717738 | Observational | NA | Recruiting | 300 | HCC Non-resectable | 1 Response Rate measured by mRECIST criteria 2 Number of Patients Amendable to Curative Surgical Interventions 3 TTP 4 PFS 5 OS 6 Pathological response 7 DCR 8 Quality of Life (QoL) |
| NCT05168163 | Interventional | II | Recruiting | 122 | HCC | 1 OS 2 PFS 3 ORR 4 DOR 5 AE |
| NCT05620771 | Interventional | II | Recruiting | 84 | HCC | 1 PFS 2 TTP 23 ORR 4 DOR 5 CBR 6 OS 7 AE |
| NCT05389527 | Interventional | II | Active, not recruiting | 43 | HCC | 1 MPR 2 PCR 3 Pathologic complete response (pCR) 4 ORR 5 R0 resection rate 6 DFS 7 OS 8 AE |
| NCT05488522 | Interventional | I | Recruiting | 18 | HCC | 1 Primary Objective 2 Secondary Objective 3 OS 4 PFS |
| NCT05101629 | Interventional | II | Active, not recruiting | 32 | HCC | 1 ORR 2 OS 3 Safety and toxicity |
| NCT05199285 | Interventional | II | Recruiting | 40 | HCC | 1 ORR 2 OS 3 PFS 4 Disease control 5 AE |
| NCT05822752 | Interventional | II | Recruiting | 120 | HCC | 1 BOR 2 DOR 3 PFS 4 OS |
| NCT05269381 | Interventional | I | Recruiting | 36 | too much | 1 AE 2 The number and percentage of participants who completed the sequencing with satisfactory data quality registration and identified at least 10 actionable peptides, meet the eligibility criteria for registration, and able to initiate vaccine production 3 Immunogenicity responders |
| NCT05327738 | Interventional | II | Withdrawn | 0 | HCC | 1 Proportion of progression-free participants 2 ORR 3 DCR 4 TTP 5 PFS 6 OS 7 Incidence of grade >= 3 adverse events |
| NCT05377034 | Interventional | II | Recruiting | 176 | Locally Advanced Hepatocellular Carcinoma | 1 BOR 2 DOR 3 TOR 4 PFS 5 OS |
| NCT05286320 | Interventional | I/II | Not yet recruiting | 27 | Unresectable Hepatocellular Carcinoma, Lenvatinib, Pembrolizumab, Stereotactic Body Radiotherapy |
1 safety rate 2 ORR 3 PFS 4 OS 5 Immune biomarkers |
| NCT06024252 | Observational | NA | Not yet recruiting | 200 | HCC | 1 OS 2 PFS 3 ORR 4 One-year survival rate 5 Immune-TACE PFS 6 DCR 7 Treatment pattern |
| NCT05448677 | Interventional | II | Recruiting | 196 | HCC | 1 PFS 2 ORR |
| NCT05223816 | Interventional | II | Recruiting | 97 | HCC, Intrahepatic Cholangiocarcinoma | 1 Safety in Cohort1 2 ORR 3 PFS |
| NCT05797805 | Interventional | I/II | Recruiting | 108 | Advanced Hepatocellular Carcinoma | 1 AE 2 DLT 3 Evaluate efficacy of tegavivint as a single agent |
| NCT05776875 | Interventional | II | Recruiting | 24 | HCC | 1 AE 2 Response rate 3 Time to progression 4 Time to TACE progression (TTTP) 5 Time to untaceable progression |
| NCT05908786 | Interventional | I/II | Recruiting | 150 | HCC | 1 MPR 2 PCR 3 Relapse-Free Survival (RFS) 4 Event-Free Survival (EFS) 5 OS |
| NCT05396937 | Interventional | II | Recruiting | 42 | HCC | 1 ORR 2 Duration of Objective Response (DoR) 3 DCR 4 TTP 5 PFS 6 OS |
| NCT05903456 | Interventional | II | Not yet recruiting | 20 | HCC | 1 ORR 2 PFS 3 OS 4 DCR 5 Disease Control Rate 6 DOR 7 AE |
| NCT06066333 | Interventional | II | Recruiting | 12 | ACC, Adrenocortical Carcinoma, Metastatic Adrenocortical Carcinoma | 1 AE |